Key result
Higher FEV1/FVC (OR 1.14) and PeakPETCO2 (OR 1.13) independently predicted vasoresponsiveness in idiopathic pulmonary arterial hypertension, with a combined score yielding an AUC of 0.80.
Why the study?
Whether cardiopulmonary exercise testing and pulmonary function tests could screen vasoresponsiveness in idiopathic pulmonary artery hypertension patients remained undefined.
Can PeakPETCO2 combined with FEV1/FVC predict vasodilator responsiveness in patients with idiopathic pulmonary arterial hypertension?
Observational (n=132)
No
Can PeakPETCO2 combined with FEV1/FVC predict vasodilator responsiveness in patients with idiopathic pulmonary arterial hypertension?
A novel scoring model combining PeakPETCO2 from cardiopulmonary exercise testing and FEV1/FVC from pulmonary function testing provides high specificity for non-invasively predicting vasodilator responsiveness in patients with idiopathic pulmonary arterial hypertension.
May support noninvasive prediction of vasodilator responsiveness in IPAH; hypothesis-generating pending prospective validation.
Cardiopulmonary exercise testing and pulmonary function test are important methods for detecting human cardio‐pulmonary function. Whether they could screen vasoresponsiveness in idiopathic pulmonary artery hypertension (IPAH) patients remains undefined. One hundred thirty‐two IPAH patients with complete data were retrospectively enrolled. Patients were classified as vasodilator‐responsive (VR) group and vasodilator‐nonresponsive (VNR) group on the basis of the acute vasodilator test. Pulmonary function test and cardiopulmonary exercise testing were assessed subsequently and all patients were confirmed by right heart catheterization. We analyzed cardiopulmonary exercise testing and pulmonary function test data and derived a prediction rule to screen vasodilator‐responsive patients in IPAH. Nineteen of VR‐IPAH and 113 of VNR‐IPAH patients were retrospectively enrolled. Compared with VNR‐IPAH patients, VR‐IPAH patients had less severe hemodynamic effects (lower RAP, m PAP, PAWP, and PVR). And VR‐IPAH patients had higher anaerobic threshold (AT), peak partial pressure of end‐tidal carbon dioxide (P ET CO 2 ), oxygen uptake efficiency (OUEP), and FEV 1 /FVC (P all <0.05), while lower peak partial pressure of end‐tidal oxygen (P ET O 2 ) and minute ventilation (VE)/carbon dioxide output (VCO 2 ) slope (P all <0.05). FEV 1 /FVC (Odds Ratio [OR]: 1.14, 95% confidence interval [CI]: 1.02–1.26, P = 0.02) and PeakP ET CO 2 (OR: 1.13, 95% CI: 1.01–1.26, P = 0.04) were independent predictors of VR adjusted for age, sex, and body mass index. A novel formula (=−16.17 + 0.123 × PeakP ET CO 2 + 0.127×FEV 1 /FVC) reached a high area under the curve value of 0.8 (P = 0.003). Combined with these parameters, the optimal cutoff value of this model for detection of VR is −1.06, with a specificity of 91% and sensitivity of 67%. Compared with VNR‐IPAH patients, VR‐IPAH patients had less severe hemodynamic effects. Higher FEV 1 /FVC and higher peak P ET CO 2 were associated with increased odds for vasoresponsiveness. A novel score combining PeakP ET CO 2 and FEV 1 /FVC provides high specificity to predict VR patients among IPAH.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2021) conducted an observational in Idiopathic pulmonary arterial hypertension (IPAH) (n=132). PeakPETCO2 and FEV1/FVC assessment vs. Vasodilator-nonresponsive (VNR) patients was evaluated on Vasodilator responsiveness predicted by FEV1/FVC (OR 1.14, 95% CI 1.02-1.26, p=0.02). Higher FEV1/FVC (OR 1.14) and PeakPETCO2 (OR 1.13) independently predicted vasoresponsiveness in idiopathic pulmonary arterial hypertension, with a combined score yielding an AUC of 0.80.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: